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The incidence of hepatocellular carcinoma (HCC) has been rising
worldwide in the past decade. During this period, major progress
has been achieved in understanding the pathophysiology, natural
history, diagnosis, staging and treatment of HCC as reﬂected in
the two recently updated guidelines of the American Association
for the Study of Liver Diseases and the European Association for
the Study of the Liver [1,2]. Both documents consider surgical
resection for small solitary tumors as a ﬁrst-line treatment option
in patients with cirrhosis and well preserved liver function, and
an hepatic vein pressure <10 mmHg (or platelet count
>100,000/mm3). This recommendation requires speciﬁc stan-
dards of care including updated surgical techniques, an expected
5-year survival rate of 60%, and a perioperative mortality of 2–
3% [2]. In addition, liver transplantation is considered to be a
ﬁrst-line treatment for patients meeting the Milan criteria who
are not suitable for resection. Local ablation with radiofrequency
(RFA) and until recently, percutaneous alcohol injection (PEI),
have been considered a standard of care for patients with BCLC
0-A tumors not suitable for surgery [2]. Three independent
meta-analyses including 5 randomized controlled trials (RCT)
have provided evidence for enhanced local control and increased
survival beneﬁts in patients treated by RFA as compared to PEI
[2]. This advantage was established despite a marginally higher
rate of major complications associated with RFA at 4% as com-
pared to 2.7% for PEI. The best results were reported for RFA-trea-
ted patients with tumors <2 cm in diameter who had 5-year
survival rates ranging from 40% to 70%. However, RFA has also
been shown to provide a survival beneﬁt in patients with tumors
>2 cm but <5 cm, as compared to PEI. Consequently RFA has pro-
gressively replaced PEI for patients with small HCC who are not
candidates for surgery. Yet, no consensus has been reached so
far whether percutaneous RFA can replace surgical resection as
ﬁrst-line treatment for small tumors. Two RCTs provided conﬂict-
ing evidence regarding the beneﬁts of RFA versus surgical resec-
tion. On the one hand, the results from one RCT suggest a beneﬁt
for surgery over RFA in patients who met the Milan criteria fol-Journal of Hepatology 20
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E-mail address: Shouval@hadassah.org.illowed for up to 5 years [3]. On the other hand, the other RCT
did not identify a signiﬁcant difference in survival between RFA
and surgery in patients with solitary HCC and a diameter up to
5 cm followed for 4 years [4].
In the present issue of the Journal, Dr. Kai Feng and co-
workers report the result of a third RCT, comparing survival
and recurrence-free survival between percutaneous RFA and
open surgical resection. The study cohort consisted of 168 Chi-
nese patients with small HCC up to a diameter of 4 cm and
not more than two nodules, selected from 2537 admitted
patients [5]. Patients were randomized to one of the groups
in a non-blinded manner, with stratiﬁcation according to
tumor diameter below or above 2 cm but <4 cm. The baseline
characteristics of the randomized patients are shown in Table 1
of whom the majority (121 patients) had hepatitis B virus
infection [5].
The primary observation of this study revealed a compara-
ble survival rate between the RFA and the surgical resection
group, with an excellent safety record for both groups, and
no mortality. The 1-, 2- and 3-year survival rates were 93.1%,
83.1%, 67.2% as compared to 96.0%, 87.6%, 74.8% for the RFA
and surgical groups respectively. The recurrence-free survival
rates were similar but somewhat lower although statistically
not signiﬁcant for the RFA treated group as compared to the
surgical group. During the 3-year follow-up, 42% and 32% of
the RFA and surgical groups respectively, had tumor recur-
rence. Multivariate analysis revealed that two risk factors,
namely decreased hepatic function, as measured by indocya-
nine green, and presence of two nodules in different hepatic
segments were associated with a poorer prognosis. Further-
more, tumor recurrence as a result of incomplete ablation
appears to be more frequent in RFA recipients as compared
to surgery when an HCC nodule is subcapsular or is adjacent
to the gall bladder or the diaphragm.
Comments: The main results of this study suggest that survival
rates and recurrence-free survival rates obtained by single RFA
treatment are comparable to open surgical resection in a sub-
group of HCC patients with tumor diameter <4 cm selected from
a large cohort of over 2500 patients. The study results do not pro-
vide unequivocal evidence for superiority of one modality over
the other. Therefore, the debate regarding the advantage of sur-
gery over RFA or vice versa for small HCC remains unresolved.
A recent retrospective national survey conducted in Japan -
which reviewed the mortality rates among 54,145 HCC patients12 vol. 57 j 713–714
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who underwent hepatectomy, RFA or transarterial embolization
(TAE) - conﬁrmed the continuous improvement in the safety of
these procedures [6]. The overall mortality rates in these patients,
irrespective of tumor characteristics, were 0.3% for RFA treated
patients, 1.0% in TAE treated patients and 2.6% in those who
underwent hepatectomy. Thus, regardless of the pros and cons
of RFA versus surgical resection, the study results of Kai Feng
et al. reafﬁrm the efﬁcacy of RFA in patients with small HCC
(<4 cm) who prefer local ablation over surgery.Conﬂict of interest
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